CXL-1020: Phase I/IIa data

In a double-blind, placebo-controlled, dose-escalating, U.S. Phase I/IIa trial in 28 patients with chronic stable heart failure, IV CXL-1020 was well tolerated up to 10 µg/kg/minute with no serious ad...